Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Proteomic biomarkers of emphysema-predominant and non-emphysema-predominant chronic obstructive pulmonary disease

Zhang YH., Castaldi PJ., Bowler RP., Pratte KA., Kinney GL., Young KA.

Prospective Study on Systemic / IV, published in EBioMedicine (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
EBioMedicine (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40505416
PMCID
PMC12192512
DOI
10.1016/j.ebiom.2025.105800
Citations
5

Abstract (original English)

Background Chronic Obstructive Pulmonary Disease (COPD) is a complex and heterogeneous disease. Emphysema-predominant and non-emphysema predominant COPD are two major disease subtypes capturing important aspects of COPD heterogeneity. Molecular differences between these COPD subtypes are unknown. Methods We assessed plasma proteomic associations (using SomaScan) with emphysema-predominant vs. non-emphysema predominant COPD subtypes in COPDGene; replication of significant associations was performed in SPIROMICS. We performed pathway analyses on COPD subtype plasma proteomic associations and used weighted gene correlation network analysis to find COPD subtype-associated protein correlation networks. We tested previously reported COPD genetic variants for association with COPD subtypes and COPD subtype-associated proteomic biomarkers. Findings One hundred and twenty-four proteins were significantly associated with COPD subtypes in COPDGene, with 64 proteins (65 SOMAmers) validated in SPIROMICS. Higher correlations were observed between proteomic biomarkers with greater expression levels in non-emphysema predominant participants with COPD. Cell adhesion, collagen-containing extracellular matrix, and epithelial mesenchymal transition were biological pathways enriched for COPD subtype proteomic associations. One COPD subtype-associated correlation network module was identified, inclu

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansPulmonary Disease, Chronic ObstructivePulmonary EmphysemaProteomeProteomicsAgedMiddle AgedFemaleMaleBiomarkers

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research